Catalent Expands Biologics Capabilities in the UK and Across Europe by Acquiring Facility in Oxfordshire
Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimise the development, launch, and supply of better patient treatments across multiple modalities, today announced the acquisition of a biologics development and manufacturing facility currently under construction near Oxford, United Kingdom, from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.).
Catalent is to spend up to $160 million (£120 million) on the facility’s completion and equipping it with cutting-edge capabilities for the research and manufacturing of biologic medicines and vaccines, including mRNA, proteins, and other advanced modalities. The new facility is intended to employ over 400 employees and support public and commercial entities that are working to develop and manufacture biotherapeutics.
The new facility is located south of Oxford at the world-renowned Harwell Science and Innovation Campus, which is home to more than 40 life science enterprises and is a premier venue in the United Kingdom for science and technology research achievements.
Catalent has a long history in the United Kingdom, with over 1,300 employees working at four facilities dedicated to the development and manufacture of oral dosage forms in Nottingham, Swindon, Haverhill, and Dartford, as well as a clinical trial supply site in Bathgate, Scotland. In addition to Italy, Belgium, France, Switzerland, and the United States, Catalent Biotherapeutics has locations in Italy, Belgium, France, Switzerland, and the United States.